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Introduction
Alfa-melanocyte stimulating hormone (a-MSH) has a
variety of biological functions such as downregulation of
pro-inflammatory pathways, reduction of skin delayed-
type hypersensitivity and blockage of leukocyte migration.
Inhibition of experimental disease models development
including inflammatory bowel disease and rheumatoid
arthritis has been shown, however the immunomodulatory
and anti-inflammatory effects of a-MSH on murine lupus
remain undetermined.
Objectives
To evaluate the effect of a-MSH analogue (NDP a-
MSH) on pristane-induced murine lupus.
Methods
Thirty-five BALB/c mice were injected with 0.5 ml intra-
peritoneal (IP) pristane for lupus-like model induction and
5 age/gender matched control mice were given saline.
Pristane-induced lupus animals received daily IP saline
(n = 5) or treatments with 3.1 mg/kg/d chloroquine (n =
10), 1.25 mg/kg/d NDP a-MSH (n = 10) or 2.5 mg/kg/d
NDP a-MSH (n = 10). Prior and 180 days after induction,
clinical and laboratorial lupus-like parameters were exam-
ined. Sera ANA was tested by IF using Hep2 cells. Statisti-
cal analysis was performed by Mann-Whitney and Fisher
test and P < 0,05 considered significant.
Results
Arthritis in both hind legs and large amounts of lipogranu-
lomas in peritoneal cavity were observed in all lupus-like
animals in contrast to all controls. By visual observation,
all lupus animals treated with both doses of a-MSH had
significant less amount and lower size lipogranulomas.
Mean arthritis score in 5 untreated mice, 9 animals treated
with chloroquine and 8 with a-MSH 2.5 mg/kg/d was 5.2,
3.33 and 3.1 respectively. Remarkably, mean arthritis score
of animals treated with a-MSH 1.25 mg/kg/d was 1.6,
significantly lower than untreated mice (1.6 vs 5.2, p =
0.0291). ANAs were negative in sera from all 40 animals
before pristane lupus injection; 180 days after induction,
ANAs remained negative in normal mice but became
positive in all 5 (100%) untreated lupus animals, 7 (77%), 4
(50%) and 3 (35%) lupus models treated with chloroquine,
a-MSH 2.5 mg/kg/d and a-MSH 1.25 mg/kg/d (100% vs
35%, p = 0,0256), respectively. Before the end of the
experiment, by day 150, 3 animals died: 1 treated with
chloroquine and 2 with higher doses of a-MSH.
Conclusion
NDP a-MSH promoted improvement of clinical and
serological parameters in pristane-induced murine lupus
suggesting a potential role for this drug in human SLE.
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